103
Participants
Start Date
September 5, 2014
Primary Completion Date
February 28, 2017
Study Completion Date
January 30, 2024
Enzalutamide
Capsules for oral administration
Trastuzumab
Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
Site BE32016, Brussels
Site BE32003, Edegem
Site BE32013, Brasschaat
Site BE32009, Leuven
Site BE32007, Liège
Site BE32001, Charleroi
Site US10048, Pittsburgh
Site IT39003, Milan
Site IT39002, Milan
Site IT39001, Sondrio
Site ES34013, Madrid
Site ES34014, Pozuelo de Alarcón
Site US10074, Gainesville
Site IT39021, Udine
Site US10079, Fort Myers
Site US10042, Nashville
Site US10077, Nashville
Site US10029, Knoxville
Site US10072, Cincinnati
Site US10004, Indianapolis
Site IT39005, Meldola
Site US10081, Chicago
Site US10078, St Louis
Site IT39008, Lecce
Site US10076, Fort Worth
Site US10082, Houston
Site US10028, Los Angeles
Site US10051, Anaheim
Site US10035, San Francisco
Site US10070, Boston
Site CA15022, Ottawa
Site CA15023, Toronto
Site CA15028, Regina
Site CA15026, Saskatoon
Site CA15001, Québec
Site ES34010, Barcelona
Site GB44003, Edinburgh
Site GB44013, Manchester
Site GB44001, Nottingham
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY